Pfizer shares slumped 3.60% following disappointing fourth quarter results that included a $1.6 billion loss compared to a $410 million profit in the same quarter of 2024. According to reports from Live Mint, the pharmaceutical giant's quarterly revenue dropped 2% to $62.6 billion, reflecting continued challenges from declining Covid-19 product sales. The company reported $4.4 billion in asset impairments due to changes in development plans and updated long-range commercial forecasts.
The quarterly results highlighted significant declines in Covid-19 related revenue streams, with Pfizer recording a 35% drop in revenue from Covid-19 vaccine Comirnaty and a 75% decline in sales tied to therapeutic drug Paxlovid during the December 2025 quarter. As reported by Live Mint, these declines continue to impact the company's overall financial performance as pandemic-related products lose their market relevance.
Pfizer forecasted 2026 revenue of $59.5 billion to $62.5 billion, slightly down from the previous year's $62.6 billion, while maintaining its R&D expenses between $10.5 billion and $11.5 billion for the year. According to Live Mint, the company plans no share buyback this year as it works to limit debt while funding research and development programs. Pfizer anticipates approximately 20 key pivotal study starts in 2026, with CEO Albert Bourla describing 2026 as an important year rich in key catalysts.
Since the pandemic, Pfizer has completed acquisitions of oncology drug specialist Seagen and weight loss products company Metsera. As reported by Live Mint, Pfizer said half of the 20 trials in 2026 are for ultra-long-acting obesity assets acquired from Metsera, with clinical trial results for anti-obesity products being encouraging. However, the company is targeting the first government approvals only in 2028, as investors seek combinations of treatments that can produce more weight loss than current medicines.
